A Single Center,Real World Experience to Determine the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir (3D regimen) With or Without Ribavirin for Treating Hepatitis C Virus Genotype 1 Infection in Patients With and Without Cirrhosis.
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2016 New trial record
- 24 May 2016 Results (n=76) presented at the Digestive Disease Week 2016.